会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model
    • 尿路上皮癌尿路上皮分化:膀胱癌干细胞模型
    • US20090047212A1
    • 2009-02-19
    • US12079078
    • 2008-03-24
    • David M. BermanWilliam MatsuiXiaobing He
    • David M. BermanWilliam MatsuiXiaobing He
    • A61K51/08A61P35/00A61K39/395A61B5/055A61K49/00A61K51/10
    • G01N33/57484A61K49/0002
    • The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and/or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.
    • 本发明提供了在有需要的患者(例如,人类患者)中治疗癌症的方法,所述方法包括施用治疗有效的方案,所述方案包括向有需要的患者施用靶向67层粘连蛋白受体( 67LR)。 在一个具体实施方案中,靶向67LR的化合物是抗体或抗体片段。 特别地,本发明提供了一种治疗癌症的方法,包括向有需要的患者施用与67LR结合的抗体。 本发明还提供了一种治疗癌症的方法,包括向有需要的患者施用抗体缀合物,其中所述抗体缀合物包含与治疗剂,蛋白质毒素,细胞毒性剂或其它部分连接的67LR结合的抗体。 本发明提供了用于治疗癌症的药物组合物,其包含以有效减少患者的癌症干细胞和/或癌细胞的量结合67LR的抗体。 本发明还提供了用于根据67LR的表达来检测和监测癌症干细胞的方法。
    • 7. 发明授权
    • Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model
    • 尿路上皮癌尿路上皮分化:膀胱癌干细胞模型
    • US08784772B2
    • 2014-07-22
    • US12079078
    • 2008-03-24
    • David M. BermanWilliam MatsuiXiaobing He
    • David M. BermanWilliam MatsuiXiaobing He
    • A61K51/08A61P35/00A61K39/395A61B5/055A61K49/00A61K51/10G01N33/48C12Q1/00
    • G01N33/57484A61K49/0002
    • The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and/or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.
    • 本发明提供了在有需要的患者(例如,人类患者)中治疗癌症的方法,所述方法包括施用治疗有效的方案,所述方案包括向有需要的患者施用靶向67层粘连蛋白受体( 67LR)。 在一个具体实施方案中,靶向67LR的化合物是抗体或抗体片段。 特别地,本发明提供了一种治疗癌症的方法,包括向有需要的患者施用与67LR结合的抗体。 本发明还提供了一种治疗癌症的方法,包括向有需要的患者施用抗体缀合物,其中所述抗体缀合物包含与治疗剂,蛋白质毒素,细胞毒性剂或其它部分连接的67LR结合的抗体。 本发明提供了用于治疗癌症的药物组合物,其包含以有效减少患者的癌症干细胞和/或癌细胞的量结合67LR的抗体。 本发明还提供了用于根据67LR的表达来检测和监测癌症干细胞的方法。